Article
A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy.
Cancer treatment and research communications - 1 Jan 2021
Baik Christina, Lee Sylvia, Cook Kitty, Wallace Sarah, Wood Rebecca, Santana-Davila Rafael, Chow Laura, Rodriguez Cristina, Eaton Keith D, Martins Renato
Abstract excerpt
BACKGROUND: Patients with metastatic non-small cell lung cancer (NSCLC) harboring a sensitizing EGFR mutation have effective targeted therapy options initially but most patients eventually progress and receive cytotoxic chemotherapy. In this single-institution phase II study, we evaluated the role of nab-paclitaxel monotherapy in this patient population. PATIENTS AND METHODS: Patients with metastatic NSCLC with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.